A Phase 1, Open-Label Clinical Trial Evaluating the Safety, Tolerability and Immunogenicity of Intradermally Administered ID-LV305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Trial Profile

A Phase 1, Open-Label Clinical Trial Evaluating the Safety, Tolerability and Immunogenicity of Intradermally Administered ID-LV305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs LV 305 (Primary)
  • Indications Breast cancer; Male breast cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Sarcoma
  • Focus Adverse reactions; First in man
  • Sponsors Immune Design
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 16 Aug 2017 Planned End Date changed from 1 Dec 2018 to 11 Aug 2020.
    • 08 Jun 2016 According to an Immune design media release, the company announced updated results of patients (n=24) with advanced or metastatic sarcoma cancers and the data was presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) annual meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top